Stay updated on Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Sign up to get notified when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.

Latest updates to the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page
- ChecktodayChange DetectedThe page's revision badge was updated from v3.5.3 to v3.5.4. This indicates a minor template or system update and does not alter study details or user-facing content.SummaryDifference0.0%

- Check7 days agoNo Change Detected
- Check15 days agoChange DetectedAdded a full bibliographic citation for Gupta et al. on enfortumab vedotin plus pembrolizumab in Future Oncology (2026) with volume, pages, DOI, and online publication date, replacing the previous abbreviated online-ahead-of-print reference in the Publications section. This update clarifies the source details for the related patient-reported outcomes study.SummaryDifference0.0%

- Check22 days agoChange DetectedRevision: v3.5.3 replaces v3.5.2. This update reflects a version bump for the page's underlying documentation and tooling.SummaryDifference0.0%

- Check29 days agoChange DetectedUpdated the page revision/version indicator from **v3.5.0** to **v3.5.2**.SummaryDifference0.0%

- Check43 days agoChange DetectedAdded a new publication citation to the Publications section: How enfortumab vedotin plus pembrolizumab affects the quality of life of people with advanced urothelial cancer: Future Oncol (2026).SummaryDifference0.0%

- Check50 days agoChange DetectedAdded a 2026 Pan-Asian subgroup analysis paper on EV-302 and removed the online-ahead-of-print version of the same article from the Publications list.SummaryDifference0.0%

Stay in the know with updates to Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Enfortumab Vedotin Combo vs. Chemo Alone in Urothelial Cancer Clinical Trial page.